Ardelyx (ARDX)

Executive Summary

Ardelyx is a biopharmaceutical company focused on developing and commercializing gut-targeted therapies for cardiorenal and metabolic diseases. Its approved products, XPHOZAH (tenapanor) for hyperphosphatemia in dialysis patients and IBSRELA (tenapanor) for IBS-C, have established commercial traction. The pipeline includes Phase 3 trials for tenapanor in cystic fibrosis and chronic idiopathic constipation (CIC), which represent significant expansion opportunities. With a growing revenue base and multiple late-stage programs, Ardelyx is positioned for sustained growth, though it faces competition and payer challenges. The company's innovative approach to gut-mediated therapeutics supports a favorable risk/reward profile.

Upcoming Catalysts (preview)

• 2027Tenapanor Phase 3 data in cystic fibrosis70% success
• 2027Tenapanor Phase 3 data in chronic idiopathic constipation (CIC)60% success
• Q4 2026Potential label expansion or partnership announcement50% success